NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer

May 29-June 2, 2015; Chicago, Illinois
Results of this phase II study indicate promising response rates and survival in both tubulin inhibitor–naive and tubulin inhibitor–exposed patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 476 KB
Released: June 4, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Updated analysis of rate of bone fractures in phase III EORTC GUCG 1333/PEACE-3 trial with or without BPAs from ASCO 2021, as reported by Clinical Care Options (CCO)

Released: June 15, 2021

Downloadable slideset covering PARP inhibitor monotherapy and determinants of response in metastatic CRPC, from Clinical Care Options (CCO)

person default Wassim Abida, MD, PhD Released: June 15, 2021

Downloadable slideset reviewing the rationale for PARP inhibitor combinations in metastatic CRPC, from Clinical Care Options (CCO)

Joaquin Mateo, MD, PhD Released: June 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue